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Aims Both left ventricular (LV) and left atrial (LA) dysfunction and remodelling contribute to adverse outcomes in
heart failure with reduced ejection fraction (HFrEF). Danicamtiv is a novel, cardiac myosin activator that enhances
cardiomyocyte contraction.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We studied the effects of danicamtiv on LV and LA function in non-clinical studies (ex vivo: skinned muscle fibres
and myofibrils; in vivo: dogs with heart failure) and in a randomized, double-blind, single- and multiple-dose phase
2a trial in patients with stable HFrEF (placebo, n = 10; danicamtiv, n = 30; 50–100mg twice daily for 7 days).
Danicamtiv increased ATPase activity and calcium sensitivity in LV and LA myofibrils/muscle fibres. In dogs with heart
failure, danicamtiv improved LV stroke volume (+10.6 mL, P < 0.05) and LA emptying fraction (+10.7%, P < 0.05).
In patients with HFrEF (mean age 60 years, 25% women, ischaemic heart disease 48%, mean LV ejection fraction
32%), treatment-emergent adverse events, mostly mild, were reported in 17 patients (57%) receiving danicamtiv and
4 patients (40%) receiving placebo. Danicamtiv (at plasma concentrations ≥2000 ng/mL) increased stroke volume (up
to +7.8 mL, P < 0.01), improved global longitudinal (up to −1.0%, P < 0.05) and circumferential strain (up to −3.3%,
P < 0.01), decreased LA minimal volume index (up to −2.4 mL/m2, P < 0.01) and increased LA function index (up to
6.1, P < 0.01), when compared with placebo.
*Corresponding author. University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Tel: +31 50 3612355, Email: a.a.voors@umcg.nl
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Conclusions Danicamtiv was well tolerated and improved LV systolic function in patients with HFrEF. A marked improvement
in LA volume and function was also observed in patients with HFrEF, consistent with pre-clinical findings of direct
activation of LA contractility.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Heart failure with reduced ejection fraction (HFrEF) is character-
ized by neurohormonal activation and left ventricular (LV) dys-
function and remodelling, both of which have been successfully
addressed, to some extent, with current medical therapies.1–3
However, both LV and left atrial (LA) dysfunction and remod-
elling likely occur in concert, and contribute to the poor prog-
nosis in HFrEF.4–7 In addition, chronic therapies directly target-
ing the myocardium are lacking and prior attempts have been
fraught with safety concerns owing to dependency on Ca2+ and/or
second-messenger signalling.2,3,8,9 A new drug class, direct cardiac
myosin activators or myotropes, offers the potential to circumvent
these prior limitations.10
Danicamtiv (formerly MYK-491) is a novel small molecule
that selectively enhances cardiac actomyosin activity, the molec-
ular force-generating unit of the sarcomere, prolonging contrac-
tion while preserving actin–myosin detachment, allowing relax-
ation, and without impacting Ca2+ homeostasis. In pre-clinical
studies, danicamtiv increased myocardial contraction with little
effect on diastolic stiffness/tension,11 findings also observed in the
first-in-man healthy volunteer study.12 Here, we aimed to evaluate
the LV and LA effects of danicamtiv in pre-clinical in vitro and in vivo
studies, and in a randomized, double-blind, single and multiple-dose
phase 2a study in patients with HFrEF.
Methods
Pre-clinical ex vivo and in vivo studies
The methods for the ex vivo biomechanical studies and the in vivo
functional studies in a dog heart failure model are described in detail
in online supplementary Methods S1.
Clinical study
This study was a randomized, double-blind, placebo-controlled trial of
danicamtiv comprising two parts: a single-ascending dose, crossover
phase 1b trial (i.e. patients received ascending doses or placebo, but
each dose only once) (see online supplementary Methods S1); and a
multiple-dose phase 2a trial (i.e. with staggered cohorts; in each cohort,
patients received the same dose or placebo repeatedly for 7 days).
The trials were conducted according to good clinical practice guide-
lines and approved by the relevant Ethics Committee at each institution
and by Regulatory Authorities in each country. All patients provided
written informed consent prior to enrolment in the study. The study
was monitored by Medpace (Cincinnati, OH, USA), coordinated by
MyoKardia (Brisbane, CA, USA) and conducted under supervision .
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. of a Safety Review Committee (SRC) (online supplementary Meth-
ods S1). The trial is registered on ClinicalTrials.gov (NCT03447990)
and in the European Clinical Trials Database (EudraCT number
2018–002239-11).
Patient population
The clinical trial enrolled patients who were 18–80 years of age
with a clinical diagnosis of stable, chronic heart failure with an LV
ejection fraction (LVEF) on echocardiography of ≤45% (subsequently
amended to ≤35%), treated with guideline-directed medical ther-
apy, and with good quality echocardiogram images. Patients were
excluded if they had renal impairment (estimated glomerular filtra-
tion rate< 30mL/min/1.73m2), if their screening cardiac troponin I
(cTnI) was elevated (value measured at the central laboratory using
Abbott Architect assay >0.15 ng/mL, with upper limit of normal [ULN]
of 0.03 ng/mL), if they had been admitted to hospital for heart fail-
ure or had an acute coronary syndrome or intervention in the previ-
ous 90 days, or had uncorrected severe valvular disease. Patients with
current or recent atrial fibrillation were also excluded. Inclusion and
exclusion criteria are listed in online supplementary Table S1.
Procedures
The study design is summarized in online supplementary Figure S1.
Enrolment in the multiple-dose trial started after eight patients had
completed the single-dose trial. Thereafter, patients could be enrolled
in either protocol and could participate in both. The multiple-dose
protocol included four cohorts (A–D) that were initiated sequentially
for enrolment after approval from an SRC. For each cohort, as a safety
precaution, a sentinel group of three patients with an LVEF ≥25%
was initially enrolled. The SRC then reviewed the relevant safety data
from this sentinel group before allowing enrolment of patients with an
LVEF of 15–25%. In cohort A, danicamtiv 75mg twice daily (BID) or
matching placebo was administered after a 2 h fast, and food was not
allowed for the following 2 h. The dose selected in cohort A was based
on pharmacokinetic (PK) simulations and initial pharmacodynamic (PD)
results obtained from the single-dose trial. In cohorts B, C and D,
patients received danicamtiv 50, 75 and 100mg BID, respectively, with
food (online supplementary Table S2).
After successful screening, patients underwent three study periods:
(1) an initial single-blind placebo run-in for 2 days (Days 1–2); (2) a
double-blind treatment period in which patients randomly received
placebo or danicamtiv (1:3) for 7 days (Days 3–9); and (3) a 1-week
follow-up period.
Clinical study objectives and endpoints
The primary objective of the study was to investigate the safety and
tolerability of single and multiple oral doses of danicamtiv in patients
with stable, chronic HFrEF.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Secondary objectives included assessment of the danicamtiv PK
profile, and evaluation of changes in the following echocardiographic
measurements, assessed in a core laboratory, with readers blinded
to study treatment and timepoint: LV stroke volume (LVSV), LVEF,
LV fractional shortening (LVFS), and LV systolic ejection time (SET),
after single and multiple doses of danicamtiv. Additional exploratory
objectives included investigation of the effect of danicamtiv on other
measures of LV and LA dimensions and function, and QT interval
corrected for heart rate on the electrocardiogram (ECG). LVSV
was derived from LV outflow tract velocity–time integral. LVEF was
calculated as LVSV divided by LV end-diastolic volume, estimated by
Simpson’s method of discs.
Serum troponin concentrations may be elevated and/or fluctuate
around the ULN in patients with HFrEF, and current guidelines do not
provide specific guidance on what constitutes a meaningful change in
serum troponin in the context of HFrEF. Therefore, the sponsor and
the SRC agreed on a study-specific definition for a rise in troponin. A
patient was considered to have a rise in troponin if one of the following
conditions was met with either cTnI or high-sensitivity troponin T
(hs-TnT), and assessed in a core laboratory: (i) troponins were within
normal ranges before the start of double-blind treatment, and at least
one troponin value obtained during or post double-blind treatment
through Day 16 was greater than twice the ULN; or (ii) troponin was
already elevated (>ULN) prior to the start of double-blind treatment,
and at least one troponin value, obtained during or post double-blind
treatment through Day 16, was increased by >0.03 ng/mL compared
with baseline.
Statistical analyses
Patients receiving placebo in the four multiple-dose cohorts (A–D)
were pooled for the analyses. No formal statistical hypothesis test-
ing was performed. Adverse events (AEs), ECGs, vital signs, labora-
tory values, plasma concentration, LVSV, LVEF, LVFS, SET, and other
echocardiographic variables, were analysed using descriptive statis-
tics. For the PK/PD analysis, echocardiographic data were paired with
the plasma concentration of danicamtiv measured at the time of the
echocardiogram. A mixed effect model was used to estimate the
placebo-corrected change from baseline for each echocardiographic
variable at each danicamtiv concentration group (low: <2000, medium:
2000 to <3500, and high: ≥3500 ng/mL). The model was separately fit-
ted for each variable, and included all data at post-baseline timepoints
when both a danicamtiv PK concentration and an echocardiogramwere
obtained, with change from time-matched baseline as the responder
variable, baseline value for the matched timepoint, PK concentration
(placebo, low, medium, or high) at the given timepoint as fixed effects,
and the patient as the random effect.
Results
Pre-clinical study results
Danicamtiv was associated with a dose-dependent increase in
sarcomere activity (ATPase turnover rate) in both ventricular
[half maximal active concentration (AC50) 6.0 μM; 95% confi-
dence interval (CI) 3.7–27.5] and atrial (AC50 3.6 μM; 95% CI
2.7–5.0) myofibrils, achieving increases [± standard deviation
(SD)] of 3.0-fold (± 0.3) and 2.3-fold (± 0.3), respectively, at 50 μM
(Figure 1A). Danicamtiv activated cardiac (human) S1 myosin
[1.4-fold (± 9) increase in ATPase rate at 3 μM], but not skeletal ..
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.. or smooth muscle isoforms. In skinned fibres, danicamtiv (at 3 μM)
shifted the tension–pCa2+ relationships leftwards (i.e. generated
greater tension at a given Ca2+ concentration), increasing Ca2+
sensitivity [pCa50 (± SD) P < 0.05 vs. pre-treatment values] of both
ventricular fibres [from 5.8 (± 0.04) to 6.1 (± 0.07); Figure 1B and
1C] and atrial fibres [from 5.7 (± 0.05) to 5.8 (± 0.10); Figure 1C],
without altering either maximal force-generation capability or
passive stiffness (online supplementary Figure S2).
In dogs with microembolization-induced heart failure, acute
treatment with danicamtiv improved LVEF [± SD] [41 (± 5)% to 51
(± 6)%; P < 0.05], LVFS [19.6 (± 2.7)% to 25.6 (± 3.6)%; P < 0.05]
and peak LV global circumferential strain [−13.5 (± 4.4)% to −17.3
(± 4.4)%; P < 0.05], leading to increases in both LVSV [33.0 (± 5.9)
mL vs. 43.6 (±10.7) mL; P < 0.05] (Figure 1D) and cardiac out-
put (online supplementary Table S3). Additionally, danicamtiv pro-
longed SET [178 (± 24) ms vs. 201 (± 29) ms; P < 0.05] (Figure 1D),
but had negligible effects on LV end-diastolic dimensions, derived
indices of ventricular filling or LV filling pressures (online supple-
mentary Table S3). In a subset of dogs instrumented for systemic/LV
haemodynamics (via telemetry), danicamtiv had no effect on sys-
temic pressures (± SD), such as systolic blood pressure [110 (± 10)
vs. 119 (±10) mmHg] or LV end-diastolic pressures [18 (± 2) to 16
(± 4) mmHg], despite a slight reduction in heart rate [108 (± 45)
to 99 (± 50) bpm; P < 0.05].
Danicamtiv also reduced LA volumes, particularly at end-diastole
[LA minimal volume index (LAminVi): 21.2 (± 8.3) mL/m2 vs. 17.9
(± 9.0) mL/m2; P < 0.05], improving both the LA emptying fraction
[LAEF: 20.4 (± 4.4)% vs. 31.1 (± 6.9)%; P < 0.05] and the LA
function index13 [LAFI: 7.7 (± 3.3)% vs. 15.2 (± 6.5)%; P < 0.05]
(Figure 1E and online supplementary Table S3).
Clinical study results
The results of the single-dose trial are presented in online sup-
plementary Tables S4 and S5. From September 2018 to October
2019, patients (n = 40) from 10 sites were randomized in the
multiple-dose trial in the USA (n = 30), the Netherlands (n = 5),
Sweden (n = 3), Germany (n = 1) and the UK (n = 1). Online
supplementary Table S2 summarizes dosing in each cohort. All
40 patients were included in the safety and PK/PD analyses.
Patient demographics and baseline characteristics are summarized
in Table 1. Baseline characteristics were similar for patients assigned
to danicamtiv or placebo, with the exception of a slight imbalance
in renal function (placebo vs. total danicamtiv).
The PK/PD analysis was based on 489 echocardiograms (Table 2
and Figure 2). Danicamtiv 50mg BID achieved a steady-state
concentration in the range of 2000 to <3500 ng/mL (medium con-
centration range; online supplementary Table S6). Treatment with
danicamtiv caused a concentration-dependent increase in LVSV
[mean placebo-corrected increase of 7.8 mL (P < 0.01) and 5.7 mL
(P < 0.05) at medium and high concentrations, respectively]. Dani-
camtiv also improved LV longitudinal as well as circumferential
strain [mean placebo-corrected decrease of −2.1% (P < 0.01)
and−3.3% (P < 0.01) at medium and high concentrations, respec-
tively], and reduced LV dimensions [mean placebo-corrected
decrease in LV end-systolic diameter of −1.3mm (P < 0.01)
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Experimental studies – effects of danicamtiv on left ventricular (LV) and left atrial (LA) function, both ex vivo (A–C) and in vivo (heart
failure dogs, D and E). Danicamtiv increased ATP turnover (ATPase) rates in LV and LA swine myofibrils (A), increasing Ca2+ sensitivity (pCa)
in fibres (B and C; B: LV tension/pCa curve); LA muscle was less Ca2+ sensitive but had faster turnover rates than the left ventricle. In dogs
with induced heart failure, danicamtiv prolonged systolic ejection time (SET), increasing indices of systolic LV function and stroke volume (D),
while decreasing size and improving performance in the left atrium (E). (A–E) Mean± standard error of the mean. (D–E) mean change (blue
text). CTRL, control; 5HR, 5 h post-treatment; LAEF, left atrial emptying fraction; LAFI, left atrial function index; LVFS, left ventricular fractional
shortening; LVSV, left ventricular stroke volume; PRE, before dosing (i.e. baseline); Volmin, minimal volume.
Table 1 Multiple-dose trial – patient demographics and baseline characteristics
Parameters Placebo (n = 10) Total danicamtiv (n = 30) Total (n = 40)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years, median (IQR) 58 (53–62) 60 (55–65) 59 (55–65)
Women, n (%) 1 (10) 9 (30) 10 (25)
White/Black, n (%) 7 (70)/3 (30) 24 (80)/6 (20) 31 (77.5)/9 (22.5)
BMI, kg/m2, median (IQR) 30 (26–36) 29 (26–33) 30 (26–35)
Ischaemic heart disease, n (%) 4 (40) 15 (50) 19 (47.5)
Time from diagnosis, years, median (IQR) 5.6 (3.9–9.1) 6.6 (1.9–10.6) 6.2 (2.4–10.0)
NYHA functional classa, n (%)
I 2 (20) 4 (13.3) 6 (15)
II 8 (80) 19 (63.3) 27 (67.5)
III 0 4 (13.3) 4 (10)
GFR, mL/min/1.73m2, median (IQR) 55 (52–75) 73 (57–83) 71 (54–82)
Guideline-recommended medical therapy, n (%)b
ACE inhibitor, ARB or sacubitril/valsartan 10 (100) 29 (96) 39 (98)
Beta-blocker 9 (90) 30 (100) 39 (98)
MRA 6 (60) 16 (53) 22 (55)
Supine systolic blood pressure, mmHg, median (IQR) 124 (110–132) 108 (104–126) 115 (105–129)
NT-proBNP, pg/mL, median (IQR) 442 (107–847) 305 (172–892) 330 (171–882)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; GFR, glomerular filtration rate; IQR, interquartile range; MRA,
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association.
aNYHA class missing in three patients.
b33% of all patients received sacubitril/valsartan.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Multiple-dose trial – change from baseline (placebo-corrected) in echocardiographic variables and vital signs
according to danicamtiv plasma concentration ranges
Baselinea (n = 40) Mean change (SE)b,c by danicamtiv plasma concentration group
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
<2000ng/mL (n = 30) 2000–<3500ng/mL (n = 26) ≥3500ng/mL (n = 13)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Plasma concentration (ng/mL)
Mean (SD) – 1169 (454) 2716 (425) 4448 (855)
Median (range) – 1220 (183–1960) 2740 (2000–3490) 4290 (3500–7520)
Main measures of LV systolic function
LVSV (mL) 59 (13) 3.1 (1.8) 7.8** (2.0) 5.7* (2.5)
LVEF (%) 32 (6) −0.3 (0.9) 1.1 (0.9) 2.3 (1.2)
LVFS (%) 18 (5) 0.5 (0.5) 0.8 (0.6) 0.5 (0.7)
SET (ms) 286 (29) 15** (3.5) 36** (3.8) 48** (4.7)
Other measures of LV systolic function
LVGLS (%) −11.2 (2) −0.3 (0.3) −0.9* (0.4) −1.0* (0.4)
LVGCS (%) −14.1 (4.3) −0.4 (0.6) −2.1** (0.7) −3.3** (0.8)
s′ (lateral) 5.2 (1.3) 0.2 (0.2) 0.6** (0.2) 0.3 (0.2)
LV dimensions and volumes
LVESD (mm) 48 (8) −0.8 (0.4) −1.3** (0.5) −1.8** (0.6)
LVEDD (mm) 58 (7) −0.6 (0.3) −0.9** (0.3) −1.8** (0.4)
LVESVi (mL/m2) 60 (22) −0.9 (1.3) −1.3 (1.4) −4.6** (1.7)
LVEDVi (mL/m2) 88 (27) −1.1 (1.5) −1.1 1.6) −5.2* (2.0)
Composite measure of systolic and diastolic function
Tei index 0.66 (0.2) −0.05 (0.03) −0.08** (0.03) −0.02 (0.03)
Relaxation/diastolic function
e′ (lateral) 6.3 (1.9) −0.2 (0.2) 0.1 (0.2) −1.0** (0.3)
E/e′(lateral) 12.4 (5.8) −0.8 (0.5) −0.7 (0.6) 0.3 (0.7)
E-wave peak (cm/s) 69 (25) −3.8 (2.1) −2.1 (2.2) −10** (2.7)
A-wave peak (cm/s) 74 (25) 4.1* (1.9) 6.1** (2.1) 4.3 (2.6)
A-wave duration (ms) 135 (25) 6.0 (3.1) 5.9 (3.3) 11.9** (4.0)
E/A ratio 1.0 (0.4) −0.1** (0.04) −0.1** (0.04) −0.2** (0.05)
IVRT (ms) 123 (24) 2.7 (5.1) 10.5 (5.4) 27.8** (6.3)
Left atrial volume and function
LAEF (%) 41 (8) 2.1 (1.2) 3.3* (1.3) 3.6* (1.6)
LAmaxVi (mL/m
2) 28 (9) −1.2 (0.6 −1.1 (0.7) −1.3 (0.8)
LAminVi (mL/m
2) 17 (7) −1.8** (0.6) −2.1** (0.6) −2.4** (0.7)
LAFI 26 (13) 2.6 (1.5) 6.1** (1.6) 5.8** (2.0)
MR jet area/LA area ratio (%) 8.7 (10.5) 0.3 (1.2) −0.6 (1.3) −4.2* (1.6)
Vital signs (supine)
Heart rate (bpm) 66 (10) 0.0 (1.1) −2.0 (1.2) −1.1 (1.6)
SBP (mmHg) 117 (18) −1.5 (1.6) −0.8 (1.8) −5.2* (2.3)
DBP (mmHg) 70 (10) −0.9 (1.0) −0.2 (1.2) −1.4 (1.5)
For the analysis, all assessments are included in the column corresponding to the danicamtiv concentration reached concomitantly to the assessments. As a result, four
patients contributed to the lower (<2000 ng/mL) danicamtiv concentration group only, 13 patients contributed to both the lower and medium (2000–<3500 ng/mL) danicamtiv
concentration groups, and 13 patients to all three danicamtiv concentration groups.
A, late peak wave velocity from mitral inflow Doppler; bpm, beats per minute; DBP, diastolic blood pressure; e′ , peak atrio-ventricular valve annular velocity in early diastole; E,
early peak wave velocity from mitral inflow Doppler; IVRT, isovolumic relaxation time; LA, left atrial; LAEF, left atrial emptying fraction; LAFI, left atrial function index; LAmaxVi,
left atrial maximum volume index; LAminVi, left atrial minimum volume index; LS, least-squares; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEDVi, left
ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESVi, left ventricular end-systolic volume index;
LVFS, left ventricular fractional shortening; LVGCS, left ventricular global circumferential strain; LVGLS, left ventricular global longitudinal strain; LVSV, left ventricular stroke
volume; MR, mitral regurgitation; SBP, systolic blood pressure; SD, standard deviation; SE, standard error; SET, systolic ejection time; TTE, transthoracic echocardiogram.
*P < 0.05. **P < 0.01.
aAbsolute arithmetic mean values (SD). bLS mean difference (SE) between each plasma concentration group (<2000 ng/mL, 2000–<3500 and ≥3500 ng/mL) and placebo
(concentration = 0) in TTE parameters’ change from baseline. cSE of LS mean difference = SE of the LS mean difference.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Multiple-dose trial – transthoracic echocardiography measurements, according to plasma concentrations of danicamtiv and change
from baseline in: (A) global circumferential strain (GCS); (B) systolic ejection time (SET); (C) left atrial function index (LAFI); and (D) change in
left ventricular stroke volume (LVSV) from baseline plotted against change in SET from baseline. The lines shown in panels A, B and C are from
a non-parametric LOESS (locally estimated scatterplot smoothing) method. The line shown in panel D, bound by the 95% upper and lower
confidence limits, was generated from a mixed model regression accounting for within patient variation due to multiple measures taken from
the same patient. Estimate of the slope is 0.1972 (P< 0.0001) with a 95% confidence interval of 0.1479–0.2465.
and−1.8mm (P < 0.01) at medium and high concentrations,
respectively]. LVEF did not change significantly. The SET increased
in a dose-dependent manner, with a mean placebo-corrected
increase of 36ms (P < 0.01) and 48ms (P < 0.01) observed at
medium and high concentrations, respectively (Figure 2B). Change
from baseline in LVSV correlated with change from baseline in SET
(Figure 2D). Danicamtiv significantly reduced LAminVi [−2.1 mL/m2
(P < 0.01) and−2.4 mL/m2 (P < 0.01) at medium and high con-
centrations, respectively], increased LAEF [+3.3% (P < 0.05) and
+3.6% (P < 0.05) at medium and high concentrations, respectively],
and improved LAFI [+6.1 (P < 0.01) and+5.8 (P < 0.01) at medium
and high concentrations, respectively]. No significant changes in
relaxation [peak atrioventricular valve annular velocity in early
diastole (e′), early peak wave velocity from mitral inflow Doppler
(E)] were observed in the medium concentration range. E/A (A
denotes late peak wave velocity from mitral inflow Doppler)
was decreased owing to an increase in A peak wave velocity. At
high concentrations, there were decreases in e′, peak E wave
(−10 cm/s; P < 0.01) and E/A. There were no changes in filling
pressures (E/e′) at medium or high concentrations. There were no
significant changes in vital signs at low and medium concentrations.
In the high concentration range, there was a small decrease in
systolic blood pressure, and no change in diastolic blood pressure
or heart rate.
No increase in QTc was observed (online supplementary Table
S7). Holter monitoring revealed no increase in atrial or ventricular
arrhythmias with danicamtiv compared with placebo (online sup-
plementary Table S8). .
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.. Treatment-emergent AEs (TEAEs) were reported in 17 patients
(57%) assigned to danicamtiv and 4 patients (40%) assigned to
placebo, with no organ specificity and no apparent relation to dose
(Table 3). All TEAEs observed with danicamtiv (except one) were
considered by investigators to be of mild intensity and/or unre-
lated to study treatment, and all TEAEs resolved without sequelae.
One patient had two episodes of non-sustained ventricular tachy-
cardia (NSVT), considered by the investigator to be of moderate
intensity and potentially related to danicamtiv. The patient also
had NSVT on Holter ECG at baseline. No TEAE led to perma-
nent treatment discontinuation or death. One serious AE of hyper-
kalaemia, which resolved, was reported in a patient who received
danicamtiv. The most common TEAEs in patients receiving dani-
camtiv (each reported in two patients) were: an increase in hepatic
transaminases (in both patients, changes were small, were con-
sidered unrelated to trial treatment, and resolved spontaneously);
contact dermatitis (in both patients, events were mild and unre-
lated to trial treatment); fatigue; and NSVT (in both patients, NSVT
was also observed on Holter ECG at baseline). A transient and
asymptomatic increase in either cTnI or hs-TnT was seen in 7
patients (23%) treated with danicamtiv (2/9 patients at 50mg, 2/15
patients at 75mg and 3/6 patients at 100mg; all 7 patients experi-
enced cTnI increase, of whom one patient treated with 100mg
also had an increase in hs-TnT) vs. none on placebo (Table 4).
None of the troponin increases observed in the multiple-dose trial
were associated with symptoms or with ECG changes suggestive
of ischaemia.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Multiple-dose trial – treatment-emergent adverse events and number of patients (%)
Total placebo
(n =10)
Danicamtiv
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cohort B
50mg BID
(n = 9)
Cohort
A+C 75mg
BID (n = 15)
Cohort D
100mg
BID (n = 6)
Total
danicamtiv
(n = 30)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No. of patients (%) with AEs
Any TEAE 4 (40.0) 7 (77.8) 6 (40.0) 4 (66.7) 17 (56.7)
Any serious TEAE 0 0 1 (6.7) 0 1 (3.3)
Any TEAE leading to permanent treatment discontinuation 0 0 0 0 0
Any AE leading to death 0 0 0 0 0
Occurred in ≥10.0% of patients in any group, n (%)
Alanine aminotransferase increased 0 1 (11.1) 1 (6.7) 0 2 (6.7)
Dermatitis contact 0 2 (22.2) 0 0 2 (6.7)
Fatigue 0 0 2 (13.3) 0 2 (6.7)
Troponin increased 0 0 1 (6.7) 1 (16.7) 2 (6.7)
Ventricular tachycardia 0 1 (11.1) 0 1 (16.7) 2 (6.7)
Anaemia 1 (10) 0 1 (6.7) 0 1 (3.3)
Abdominal discomfort 0 1 (11.1) 0 0 1 (3.3)
Application site erosion 0 1 (11.1) 0 0 1 (3.3)
Arthropod bite 0 0 0 1 (16.7) 1 (3.3)
Blood creatinine increased 0 0 0 1 (16.7) 1 (3.3)
Blood creatine phosphokinase increased 0 1 (11.1) 0 0 1 (3.3)
Cough 1 (10) 0 1 (6.7) 0 1 (3.3)
Fluid overload 0 1 (11.1) 0 0 1 (3.3)
Gingival pain 0 0 0 1 (16.7) 1 (3.3)
Hyperkalaemia 0 0 1(6.7) 0 1 (3.3)
Infusion site erythema 0 1 (11.1) 0 0 1 (3.3)
Rash 0 1 (11.1) 0 0 1 (3.3)
Arthralgia 1 (10) 0 0 0 0
Back pain 1 (10) 0 0 0 0
Dry eye 1 (10) 0 0 0 0
Nasopharyngitis 1 (10) 0 0 0 0
Renal failure 1 (10) 0 0 0 0
Renal impairment 1 (10) 0 0 0 0
Testicular pain 1 (10) 0 0 0 0
AE, adverse event; BID, twice daily; TEAE, treatment-emergent adverse event.
In the single-dose trial (described in online supplementaryMeth-
ods S1), one case of troponin increase was assessed as a possible
myocardial injury by the SRC. The event occurred in a 67-year-old
patient with a history of ischaemic heart disease. Approximately
12–24 h after receiving danicamtiv 550mg, the patient complained
of moderate dyspnoea and chest discomfort. cTnI increased from
<0.03 ng/mL to 0.12 ng/mL at 24 h post dose. There were no new
concomitant ECG changes suggestive of ischaemia. Serum cTnI
began to decrease 36 h after dosing and returned to normal 7 days
after dosing. The patient’s plasma danicamtiv concentrations during
the episode were in the range 3400–4900 ng/mL, which was simi-
lar to those observed in other patients without troponin increase.
The event resolved without intervention.
Discussion
These studies confirm that danicamtiv increased ATPase activ-
ity and Ca2+ sensitivity in myofibrils/fibres from both LA and .
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..
. LV chambers, leading to improved atrial and ventricular dimen-
sion/function in both patients with HFrEF and in an experimental
model of the disease. Danicamtiv appeared to be well tolerated
with small and asymptomatic increases in troponin observed in
some patients.
Cardiac myosin activators enhance myofibrillar ATPase activity,
leading to Ca2+-independent increases in both myocardial contrac-
tility and the duration of systole (i.e. SET),10 all features shared
by danicamtiv and now supported by both pre-clinical and clini-
cal observations. However, danicamtiv is also a selective and direct
activator of cardiac actomyosin which does not hinder the maximal
force production of the ventricular myocardium.14–17 Moreover,
danicamtiv directly increases force production in LA fibres, known
to consist of intrinsically weaker (alpha) myosin motors,18 further
highlighting its ability to preserve/enhance myosin’s intrinsic power
generation (power stroke).
Preliminary analyses of danicamtiv efficacy data in patients
with HFrEF showed multiple PD effects. Danicamtiv caused a
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Multiple-dose trial – serum troponin
concentrations
Placebo Total
danicamtiv
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Troponin I (ng/mL, ULN = 0.03) (n =10) (n = 30)
Median baseline 0.010 0.010
Median change from baseline
(max change)
0.005 (0.03) 0.010 (0.87)
Median peak troponin post
dose (max peak)
0.020 (0.05) 0.025 (0.88)
hs-troponin Ta
(ng/mL, ULN = 0.014)
(n = 7) (n = 22)
Median baseline 0.023 0.015
Median change from baseline
(max change)
0.002 (0.005) 0.005 (0.041)
Median peak troponin post
dose (max peak)
0.025 (0.032) 0.020 (0.052)
hs, high-sensitivity; ULN, upper limit of normal.
ahs-troponin T assessment added after study had started.
concentration-dependent increase in SET (up to 48ms in the high
concentration range) and increases in multiple measures of cardiac
contractility, consistent with its mode of action. The SET pro-
longation was associated, as expected, with significant increases
in stroke volume and reductions in LV dimensions. An increase
in LVEF was not observed in the multiple-dose, parallel-group
trial, but was observed in the single-dose, crossover trial (online
supplementary Table S4). This may reflect the greater variation
in measurement of LVEF among patients rather than within an
individual. However, danicamtiv did improve other direct mea-
sures of systolic dysfunction, including LV global longitudinal and
circumferential strain, which may be more sensitive markers
of contractile function than derived volumetric-based ejection
fraction.
Uniquely, danicamtiv preserves the detachment (relaxation)
steps of the actin–myosin chemo-mechanical cycle, and has
been shown not to affect end-diastolic stiffness (in dogs and in
3D-engineered tissues).11 At plasma concentrations of danicam-
tiv between 2000 ng/mL and<3500 ng/mL, and consistent with
findings in an experimental model of heart failure, no impairment
in diastolic function was observed. At higher concentrations, a
reduction in both early LV filling rate (peak E-wave) and mitral
annulus tissue Doppler displacement (e′) was noted, suggesting
possible impairment of diastolic function which could be due to
a danicamtiv-induced formation of excess cross-bridges during
systole (not to impaired detachment kinetics) as indicated by both
the concomitant prolongation of SET and isovolumic relaxation
time at these higher exposures. However, E/e′ and LA volumes
did not increase, suggesting that such changes were not asso-
ciated with an increase in cardiac filling pressures. Moreover,
since forward flow (SV) remained enhanced, any effects of the
potentially slowed relaxation on diastolic filling may have been
offset by improved atrial systolic performance, in the setting of
unaltered ventricular stiffness. Since diastolic dysfunction may ..
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.. contribute to morbidity in HFrEF,19,20 treatment with a cardiac
myosin activator that preserves relaxation may lead to enhanced
clinical benefits.
Consistent with the pre-clinical ex vivo and in vivo findings of
direct atrial activation, danicamtiv had pronounced effects on LA
volume and function, with concentration-dependent reductions
in LA minimum volume and increases in LAEF and LAFI. In the
high concentration range, a reduction in mitral valve regurgitation
was also observed, perhaps reflecting reductions in mitral annular
circumference and improvements in papillary muscle function.
Whether long-term chronic treatment with danicamtiv leads to
sustained atrial remodelling and the associated clinical benefits
remains to be determined. LA volume and function indices have
been shown in observational studies to be powerful independent
predictors of cardiovascular outcomes.4,7,21–26
In this phase 2a study, danicamtiv 50–100mg BID appeared
generally well tolerated, with a pattern of AEs that had no obvi-
ous relation to dose; although, perhaps, the most significant
event occurred with the highest dose (550mg) of danicamtiv. As
assessed by the SRC, there were no clinical ischaemic events or
myocardial infarctions, and no evidence for increased atrial or
ventricular arrhythmias. No hypotension was observed. Treatment
with danicamtiv was associated with a small and transient increase
in serum cardiac troponin in some patients. Prolonged (20-week)
treatment with omecamtiv mecarbil, another cardiac myosin acti-
vator, was also associated with troponin increase.27 The underlying
mechanisms and long-term consequences of increases in serum
troponin are currently unknown. Troponin is present in cardiac
myocytes, either attached to the contractile apparatus or detached
from it, in the cytosol.28 Release of cytosolic troponin probably
accounts for the rise in serum troponin during exercise, and does
not appear to have adverse consequences. However, in patients
with chronic, stable heart failure, with or without ischaemic heart
disease, serum troponin is often elevated, and this is associated
with a worse prognosis.29,30 The results of GALACTIC-HF, a
randomized, placebo-controlled trial of omecamtiv mecarbil con-
ducted in more than 8000 patients with HFrEF should be reported
soon, and will determine whether these small increases in serum
troponin, observed in the context of cardiac myosin activation,
are clinically important.31
Danicamtiv appears to share some common features with
omecamtiv mecarbil, such as leveraging cardiac myosin to activate
the sarcomere, increasing SET, improving LV systolic function, with
potential impact on diastolic function and relaxation at higher
concentrations. Both agents are associated with a small rise in
troponin and are generally well tolerated. Yet, the mode of inter-
action with cardiac myosin at the biochemical level and its resulting
mode of force production differ between the two agents.11,14–17
Pre-clinical evidence and data from the phase 2a study suggest a
direct effect of danicamtiv on atrial contractility. Ultimately, optimal
dosing and therapeutic windows, and how potential differences
will translate in the clinical setting remain to be determined.
The current study has several limitations: small number of
patients, exclusion of some key patient segments (e.g. very low esti-
mated glomerular filtration rate <30mL/min/1.73m2, patient with
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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atrial fibrillation, patients with advanced heart failure), low propor-
tion of patients treated with latest most effective HFrEF therapies
(sacubitril/valsartan, sodium–glucose co-transporter 2 inhibitors),
short duration of exposure, and limited number of dosing regimens
studied. In this multiple-dose trial, most of the effects of danicamtiv
were dose-dependent; 50mg BID led to steady-state concentra-
tions mostly in the range of 2000 to <3500 ng/mL (online supple-
mentary Table S6) and appeared to be effective; however, a lower
dose might also have shown some efficacy. In addition, 100mg
BID was well tolerated, therefore the maximum tolerated dose
was not clearly identified. Future, larger trials of danicamtiv with
longer treatment duration will be needed to assess optimal dosing,
safety/tolerability, LV and LA reverse remodelling, and effects on
N-terminal pro B-type natriuretic peptide (NT-proBNP).
There are currently at least eight therapeutic interventions that
are known to improve morbidity and mortality in patients with
HFrEF, and none of these interventions address intrinsic cardiac
contractility and activate cardiac myosin, therefore it is expected
that danicamtiv could be added to such treatments. Although some
patients may benefit from combining most of these treatments,
for others, a personalized approach based on comorbidities might
be more suitable. Cardiac myosin activators might be specifically
attractive for patients with low blood pressure, poor renal function,
a very low LVEF, patients at high risk of recurrent heart failure hos-
pitalization, i.e. with current or recent heart failure hospitalization
and elevated NT-proBNP (populations studied in recently com-
pleted VICTORIA trial32 and in ongoing GALACTIC-HF trial31) or
advanced heart failure (highly symptomatic, with signs and symp-
toms of congestion, and refractory to current therapies) because of
their direct effects on myocardial function and their neutral effects
on renal function, electrolytes and blood pressure. In addition, it
would be worthwhile to study the effects of danicamtiv on recur-
rence of atrial fibrillation in patients with HFrEF at risk, owing to its
favourable direct effects on LA volume and function. Lastly, the min-
imal effect on relaxation may translate into further clinical benefits
in selected patients.
In conclusion, danicamtiv, a novel, small-molecule, selective, car-
diac myosin activator, administered for 7 days, improved LV volume
and function, without impairing relaxation, and was generally well
tolerated in patients with HFrEF. Consistent with non-clinical ex
vivo and in vivo findings of direct atrial activation, danicamtiv also
markedly improved LA volume and function in patients with HFrEF.
The observed effects of improved LV systolic function combined
with the direct activation of LA contractility warrant further inves-
tigation in larger, longer term studies to determine the clinical
utility of danicamtiv.
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